US FDA approves Merck immunotherapy/chemo combo for lung cancer – Reuters
Reuters |
US FDA approves Merck immunotherapy/chemo combo for lung cancer
Reuters A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck’s pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky. Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy ApprovalTheStreet.com FDA approves Merck immunotherapy/chemo combo for lung cancerChannel NewsAsia FDA Approves Keytruda Combo for Lung CancerCuretoday.com BioPharma Dive –Forbes all 27 news articles » |
Oncology Nursing News |
Rajni Kannan on Managing Patients on Combination Immunotherapy
Oncology Nursing News Rajni Kannan, BS, MS, RN, ANP-BC, of NYU Langone—Perlmutter Cancer Center—discusses the importance of keeping up with patients who have received combination immunotherapy. Combination immunotherapy can often have intense and quick-acting … |
TheStreet.com |
Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval
TheStreet.com FDA approvals of immunotherapies used alone to treat various cancers have become almost routine, but the agency’s latest affirmative nod to Merck marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more … US FDA approves Merck immunotherapy/chemo combo for lung cancerReuters Merck boosted by FDA approval for Keytruda use with chemoFinancial Times |